# Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer

> **NCT00215644** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 72 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Matuzumab
- **DRUG:** Epirubicin
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00215644
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08-31
- **Primary completion:** 2008-07-31
- **Final completion:** 2008-08-31
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2018-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215644, "Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00215644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*